Cargando…

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status

BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of B...

Descripción completa

Detalles Bibliográficos
Autores principales: Olafsdottir, Elinborg J., Borg, Ake, Jensen, Maj-Britt, Gerdes, Anne-Marie, Johansson, Anna L. V., Barkardottir, Rosa B., Johannsson, Oskar T., Ejlertsen, Bent, Sønderstrup, Ida Marie Heeholm, Hovig, Eivind, Lænkholm, Anne-Vibeke, Hansen, Thomas van Overeem, Olafsdottir, Gudridur H., Rossing, Maria, Jonasson, Jon G., Sigurdsson, Stefan, Loman, Niklas, Nilsson, Martin P., Narod, Steven A., Tryggvadottir, Laufey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686356/
https://www.ncbi.nlm.nih.gov/pubmed/32939053
http://dx.doi.org/10.1038/s41416-020-01056-4
_version_ 1783613317348065280
author Olafsdottir, Elinborg J.
Borg, Ake
Jensen, Maj-Britt
Gerdes, Anne-Marie
Johansson, Anna L. V.
Barkardottir, Rosa B.
Johannsson, Oskar T.
Ejlertsen, Bent
Sønderstrup, Ida Marie Heeholm
Hovig, Eivind
Lænkholm, Anne-Vibeke
Hansen, Thomas van Overeem
Olafsdottir, Gudridur H.
Rossing, Maria
Jonasson, Jon G.
Sigurdsson, Stefan
Loman, Niklas
Nilsson, Martin P.
Narod, Steven A.
Tryggvadottir, Laufey
author_facet Olafsdottir, Elinborg J.
Borg, Ake
Jensen, Maj-Britt
Gerdes, Anne-Marie
Johansson, Anna L. V.
Barkardottir, Rosa B.
Johannsson, Oskar T.
Ejlertsen, Bent
Sønderstrup, Ida Marie Heeholm
Hovig, Eivind
Lænkholm, Anne-Vibeke
Hansen, Thomas van Overeem
Olafsdottir, Gudridur H.
Rossing, Maria
Jonasson, Jon G.
Sigurdsson, Stefan
Loman, Niklas
Nilsson, Martin P.
Narod, Steven A.
Tryggvadottir, Laufey
author_sort Olafsdottir, Elinborg J.
collection PubMed
description BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.
format Online
Article
Text
id pubmed-7686356
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76863562021-09-17 Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status Olafsdottir, Elinborg J. Borg, Ake Jensen, Maj-Britt Gerdes, Anne-Marie Johansson, Anna L. V. Barkardottir, Rosa B. Johannsson, Oskar T. Ejlertsen, Bent Sønderstrup, Ida Marie Heeholm Hovig, Eivind Lænkholm, Anne-Vibeke Hansen, Thomas van Overeem Olafsdottir, Gudridur H. Rossing, Maria Jonasson, Jon G. Sigurdsson, Stefan Loman, Niklas Nilsson, Martin P. Narod, Steven A. Tryggvadottir, Laufey Br J Cancer Article BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones. Nature Publishing Group UK 2020-09-17 2020-11-24 /pmc/articles/PMC7686356/ /pubmed/32939053 http://dx.doi.org/10.1038/s41416-020-01056-4 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Olafsdottir, Elinborg J.
Borg, Ake
Jensen, Maj-Britt
Gerdes, Anne-Marie
Johansson, Anna L. V.
Barkardottir, Rosa B.
Johannsson, Oskar T.
Ejlertsen, Bent
Sønderstrup, Ida Marie Heeholm
Hovig, Eivind
Lænkholm, Anne-Vibeke
Hansen, Thomas van Overeem
Olafsdottir, Gudridur H.
Rossing, Maria
Jonasson, Jon G.
Sigurdsson, Stefan
Loman, Niklas
Nilsson, Martin P.
Narod, Steven A.
Tryggvadottir, Laufey
Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title_full Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title_fullStr Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title_full_unstemmed Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title_short Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
title_sort breast cancer survival in nordic brca2 mutation carriers—unconventional association with oestrogen receptor status
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686356/
https://www.ncbi.nlm.nih.gov/pubmed/32939053
http://dx.doi.org/10.1038/s41416-020-01056-4
work_keys_str_mv AT olafsdottirelinborgj breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT borgake breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT jensenmajbritt breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT gerdesannemarie breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT johanssonannalv breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT barkardottirrosab breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT johannssonoskart breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT ejlertsenbent breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT sønderstrupidamarieheeholm breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT hovigeivind breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT lænkholmannevibeke breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT hansenthomasvanovereem breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT olafsdottirgudridurh breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT rossingmaria breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT jonassonjong breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT sigurdssonstefan breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT lomanniklas breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT nilssonmartinp breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT narodstevena breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus
AT tryggvadottirlaufey breastcancersurvivalinnordicbrca2mutationcarriersunconventionalassociationwithoestrogenreceptorstatus